The study revealed that, as compared to standard care, the use of azithromycin was linked with an increased risk of acute heart failure and death in patients with preexisting cardiovascular disease who were hospitalized with COVID-19. In patients with no history of cardiovascular disease, azithromycin had no effect on the risk. In individuals with prior CVD, azithromycin was associated with a 48% higher risk of acute heart failure but not with an increased mortality risk. In contrast, azithromycin was associated with a 43% reduction in mortality risk in patients with no prior CVD and no significant increase in the risk of acute heart failure. Patients with preexisting CVD had a higher risk of death than those who did not. Acute cardiac failure was also seen.

To know more: About the original article click here.